In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Leukemia Research

Volumn 33, Issue 1, 2009, Pages 46-53

  Lönnerholm, Gudmar ^a   Thörn, Ingrid ^a   Sundström, Christer ^a   Frost, Britt Marie ^a   Abrahamsson, Jonas ^b   Behrendtz, Mikael ^c   Heldrup, Jesper ^d   Jacobsson, Stefan ^e   Li, AiHong ^f   Olofsson, Tor ^g   Porwit, Anna ^h   Söderhäll, Stefan ^h   Larsson, Rolf ⁱ   Forestier, Erik ^f  

^a UPPSALA UNIVERSITY   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute lymphoblastic leukemia; Childhood; Doxorubicin; In vitro drug resistance; MRD; Prednisolone; t(12 ; 21)

Indexed keywords

ASPARAGINASE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; PREDNISOLONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; DOXORUBICIN; HUMANS; INFANT; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISOLONE;

EID: 55049113568     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.06.012     Document Type: Article

References (36)

1. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 83 Suppl 1 (2004) S121-S123
2. Nyvold C., Madsen H.O., Ryder L.P., Seyfarth J., Svejgaard A., Clausen N., et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 99 4 (2002) 1253-1258
3. Pui C.H., Relling M.V., and Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 350 15 (2004) 1535-1548
4. Cazzaniga G., and Biondi A. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology. Haematologica 90 3 (2005) 382-390
5. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., Biondi A., Pongers-Willemse M.J., Corral L., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352 9142 (1998) 1731-1738
6. Kaspers G.J., Veerman A.J., Pieters R., Van Zantwijk C.H., Smets L.A., Van Wering E.R., et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 90 7 (1997) 2723-2729
7. Hongo T., Yajima S., Sakurai M., Horikoshi Y., and Hanada R. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood 89 8 (1997) 2959-2965
8. Frost B.M., Nygren P., Gustafsson G., Forestier E., Jonsson O.G., Kanerva J., et al. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lymphoblastic leukaemia. Br J Haematol 122 3 (2003) 376-385
9. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Korholz D., et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21 17 (2003) 3262-3268
10. De Haas V., Kaspers G.J., Oosten L., Bresters D., Pieters R., van der Velden V.H., et al. Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?. Br J Haematol 118 4 (2002) 1190-1191
11. Schmiegelow K., Nyvold C., Seyfarth J., Pieters R., Rottier M.M., Knabe N., et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia 15 7 (2001) 1066-1071
12. Nygren P., Kristensen J., Jonsson B., Sundstrom C., Lonnerholm G., Kreuger A., et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6 11 (1992) 1121-1128
13. Larsson R., and Nygren P. Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemia. Eur J Cancer 29A 8 (1993) 1208-1212
14. Bene M.C., Castoldi G., Knapp W., Ludwig W.D., Matutes E., Orfao A., et al. Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of leukemias (EGIL). Leukemia 9 10 (1995) 1783-1786
15. In: Mitelman F. (Ed). An international system for human cytogenetic nomenclature (1995), Karger S, Basel
16. Forestier E., et al. Cytogenetic findings in a population-based series of 787 childhood acute lymphoblastic leukemias from the Nordic countries. Eur J Haematol 64 3 (2000) 194-200
17. Forestier E., et al. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. Br J Haematol 110 1 (2000) 147-153
18. Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome abberations in cancer. In: http://cgap.nci.nih.gov/Chromosomes/Mitelman; 2007.
19. Nygren P., Fridborg H., Csoka K., Sundstrom C., de la Torre M., Kristensen J., et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56 5 (1994) 715-720
20. Larsson R., Kristensen J., Sandberg C., and Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50 2 (1992) 177-185
21. Fridborg H., Jonsson E., Nygren P., and Larsson R. Relationship between diagnosis-specific activity of cytotoxic drugs in fresh human tumour cells ex vivo and in the clinic. Eur J Cancer 35 3 (1999) 424-432
22. Frost B.M., Forestier E., Gustafsson G., Nygren P., Hellebostad M., Jonsson O.G., et al. Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia. Blood 104 8 (2004) 2452-2457
23. Willems P., et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Blood 96 1 (2000) 63-70
24. Kuppers R., Zhao M., Rajewsky K., and Hansmann M.L. Detection of clonal B cell populations in paraffin-embedded tissues by polymerase chain reaction. Am J Pathol 143 1 (1993) 230-239
25. Deane M., and Norton J.D. Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias. Eur J Immunol 20 10 (1990) 2209-2217
26. Verhagen O.J., Willemse M.J., Breunis W.B., Wijkhuijs A.J., Jacobs D.C., Joosten S.A., et al. Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14 8 (2000) 1426-1435
27. van der Velden V.H., Wijkhuijs J.M., Jacobs D.C., van Wering E.R., and van Dongen J.J. T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 16 7 (2002) 1372-1380
28. van der Velden V.H., Willemse M.J., van der Schoot C.E., Hahlen K., van Wering E.R., and van Dongen J.J. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 16 5 (2002) 928-936
29. Langerak A.W., Wolvers-Tettero I.L., van Gastel-Mol E.J., Oud M.E., and van Dongen J.J. Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood 98 8 (2001) 2456-2465
30. Donovan J.W., Ladetto M., Zou G., Neuberg D., Poor C., Bowers D., et al. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. Blood 95 8 (2000) 2651-2658
31. van der Velden V.H., Cazzaniga G., Schrauder A., Hancock J., Bader P., Panzer-Grumayer E.R., et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21 4 (2007) 604-611
32. Pongers-Willemse M.J., Verhagen O.J., Tibbe G.J., Wijkhuijs A.J., de Haas V., Roovers E., et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12 12 (1998) 2006-2014
33. Kaspers G.J., Pieters R., Van Zantwijk C.H., Van Wering E.R., Van Der Does-Van Den Berg A., and Veerman A.J. Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs. Blood 92 1 (1998) 259-266
34. Lugthart S., Cheok M.H., den Boer M.L., Yang W., Holleman A., Cheng C., et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7 4 (2005) 375-386
35. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 351 6 (2004) 533-542
36. Mullighan C.G., Goorha S., Radtke I., Miller C.B., Coustan-Smith E., Dalton J.D., et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446 7137 (2007) 758-764